Radionuclide and hybrid imaging of recurrent prostate cancer.
about
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and reportPET and MR imaging: the odd couple or a match made in heaven?Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective.Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.GCPII imaging and cancer.Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.Comparison of two peptide radiotracers for prostate carcinoma targetingRecurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.Functional imaging for prostate cancer: therapeutic implications.Tissue biomarkers for prostate cancer radiation therapy.Pictorial review of SPECT/CT imaging applications in clinical nuclear medicineIntegration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapyRadiolabeled bombesin derivatives for preclinical oncological imaging.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.Prospects in radionuclide imaging of prostate cancer.PET/MR: a paradigm shift.PET/MR in prostate cancer: technical aspects and potential diagnostic value.RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.Metal-Based PSMA Radioligands.Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [68Ga]-Labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron Emission Tomography) Tracer.(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.Measurement of SUVs-maximum for normal region using VOI in PET/MRI and PET/CT.Writing PET into existence.PET/MRI and prostate cancer
P2860
Q26747480-CC719B94-4C3F-4DE4-BA9E-1D150801007BQ26851721-C3DFA99C-893E-4918-AE29-6DAA9FE34818Q30422070-FCD01D07-5286-44B6-83A0-C17213BE8366Q30976248-9380BA9D-F905-4208-90E0-20758EB77833Q31145236-497FFDCA-4008-4BD0-9022-79FEA9084A29Q33827632-8770708E-4272-4E83-BDE1-784A6E35FBCEQ34139498-24C4AB51-7766-4792-9FC3-3750D8292529Q34167447-4C99B458-26ED-4F07-92DB-4EFB88B86716Q34522627-EF430816-C3F7-4AA6-AE62-222643DBE9D1Q34995973-64C1970F-13DD-4C5B-BBF5-90A96715C050Q35877470-20CD9EAD-2136-4ECF-BCE0-FA10E718BFBAQ36128629-8ECCC74F-52F0-43B6-9030-BDC27A9B5809Q36141341-85A65B09-E977-492E-AEA2-6A756FD413E6Q36337252-89B1EA22-495A-49D0-B01F-2D8C38F30847Q36942136-3665746A-D09C-4269-A3E0-4EC2DC7199F9Q37214430-7F6FF93E-6366-4C95-9D18-35C8B476EEC9Q37674035-B7FDF4F7-DA4E-4517-95ED-789D56EDD0CCQ37918311-8E0F704A-19F9-4580-9860-90EB12149492Q37962869-B58414B9-E0EE-493A-8703-78B9A35D2D79Q38085153-F833BC85-7A7E-4A82-8032-A291B7332EF0Q38109083-C7154280-20F2-4DA7-B45D-F2A4FF00E775Q38161395-ED0E1AC5-DAD6-44A8-9D82-5505C03BCC3CQ38190115-D8B453C7-2937-49EE-B141-4B45E53F3B11Q38924532-C8A19BD3-4B71-4AF5-B34C-C3A13B3AA0A4Q39198527-91FA7295-CF71-4FBA-95BE-711C3CAF1246Q39737595-8A067A6A-1B97-4A98-A4A5-464E3AEA87A5Q39922053-C8307F8B-FC43-4555-A0D4-A4AC287774B8Q42371661-6C8D3357-DB57-4078-A579-E4C65CA65C62Q42379564-F99B2CC8-C40F-4E2F-9EF2-5895CCFE31BDQ45038526-8564A974-CF72-4F12-90DF-F4D4C78A6148Q50504575-8C6C9F95-FD55-4E9C-A1A3-92AEA78D73DBQ52665542-ECACCF95-C5B9-4A97-9CD4-7EC9B737A9EFQ52985772-361336EE-41BD-4BBF-901E-DAC8FF4A8F07Q53073093-26CDFD42-25FF-4FB6-A91A-5B8A39E2C5D1Q53094162-D290B315-834F-4051-9E94-AFF521F3C1BDQ57780524-A1CED634-FCF0-4B29-9D00-0A138E7CA1EB
P2860
Radionuclide and hybrid imaging of recurrent prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radionuclide and hybrid imaging of recurrent prostate cancer.
@en
Radionuclide and hybrid imaging of recurrent prostate cancer.
@nl
type
label
Radionuclide and hybrid imaging of recurrent prostate cancer.
@en
Radionuclide and hybrid imaging of recurrent prostate cancer.
@nl
prefLabel
Radionuclide and hybrid imaging of recurrent prostate cancer.
@en
Radionuclide and hybrid imaging of recurrent prostate cancer.
@nl
P2093
P1433
P1476
Radionuclide and hybrid imaging of recurrent prostate cancer.
@en
P2093
Ambros J Beer
Bernd Joachim Krause
Matthias Eiber
Michael Souvatzoglou
P304
P356
10.1016/S1470-2045(10)70103-0
P577
2010-07-06T00:00:00Z